Next generation digital firms for Europe wanted
pharmafile | July 15, 2013 | News story | Medical Communications, Sales and Marketing | J&J, JJ, digital, innovation
Digital health start-ups from across Europe are being called on to form a part of Johnson & Johnson Innovation’s inaugural ‘Digital Health Masterclass’.
J&J says it is offering up a springboard for the digital health influencers of tomorrow, with the firm also dishing out its years of expertise in innovation to help businesses achieve their next level of growth.
Led by experts from across the organisation including the entrepreneurial team Janssen Healthcare Innovation, Johnson & Johnson Innovation Centre London, Consumer Health and Lifescan – the Masterclass will provide access to a panel of international influencers and investors who will lead educational workshops and offer targeted advice and mentoring.
In addition to networking sessions, the successful applicants will also be invited to take part in a ‘Masterclass Challenge’ where they will pitch to a panel of experts and investors for the chance to share in a prize of €50,000.
Marco Mohwinckel, head of Janssen Healthcare Innovation Europe, said: “Johnson & Johnson is committed to leading change through innovation and we know all too well about the importance of collaboration. It’s for this reason we are pooling our expertise in healthcare and innovation to launch our first Digital Health Masterclass in Europe and offer much-needed support to these rising stars.”
The Masterclass is open to up to 20 European digital health businesses and will be delivered over three separate events in London, Barcelona and Berlin. The programme kicks-off with the first of the three-day workshops on 18 September in Berlin and will culminate with the Masterclass Challenge, which will be held in association with Health 2.0 in London on 20 November.
How to apply
J&J stipulates companies must have forward-thinking digital health solutions to take to the market, and share its philosophy to tackle some of the greatest challenges in healthcare.
To apply or find out more, visit here. Applications close: Friday 9 August.
Brett Wells
Related Content
J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …
